Not for release or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction where such release or distribution would be unlawful. Please see the important notice at the end of this announcement.
- Sales of EUR 11.1 million* in first half of 2023 around 90 percent up on same period of the previous year
- EBITDA after the first quarter of 2023 also positive in first half of 2023
- Sales growth in fiscal year 2023 expected to be in the higher double-digit percentage range compared to the previous year and a break-even result at EBITDA level
- Examining various financing options including capital market financing to support further growth
Berlin, July 20, 2023 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01), a leading European company for the production and distribution of cannabis-based pharmaceuticals, generated sales of approximately EUR 11.1 million* in the first half of 2023 representing growth of approximately 90% compared to the same period of the previous year (H1 2022: EUR 5.8 million*). Following first-time profitable growth in the first quarter of 2023, this was also achieved in the first half of 2023 with a cumulative EBITDA of EUR 0.2 million*.
“Our strong and profitable growth in the first half of fiscal year 2023 underscores the performance of our business model. For fiscal year 2023 as a whole, we expect sales growth to be in the higher double-digit percentage range compared to the previous year. At the same time, we are aiming to remain operationally profitable. In order to further support our future growth, we are also currently reviewing various financing options including capital market financing,” said Bernd Fischer, CFO of Cantourage.
“The current changes in our market environment offer opportunities for companies that are quick to adapt and innovate. For example, the draft legislation recently presented by the German Federal Ministry of Health, which, among other measures, would remove the classification of medical cannabis as a narcotic, could make it much easier access to medical cannabis and strengthen our market position. Thanks to our expertise in the production of high-quality medical cannabis products, we are well prepared to benefit from such market developments,” added Philip Schetter, CEO of Cantourage.
* The stated values refer to an unaudited pro forma consolidation of the operating subsidiaries as if they had already been acquired on 1 January of a year.
Cantourage is a leading European producer and distributor of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on November 11, 2022 and is listed under ticker symbol “HIGH”.
More information: www.cantourage.com
This announcement does not constitute a public offer or an advertisement for a public offer in the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company’s financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.
In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors in the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as “Relevant Persons”). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.
Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.
Press contact Cantourage:
M +49 (0)30 4701 350-50